Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 476-479

  Zhang, Songwen ^a   Liu, Qiangyuan ^a   Wang, Juan ^a   Harnish, Douglas C ^a  

^a PFIZER INC   (United States)

Author keywords

C reactive protein; Farnesoid X receptor (FXR) agonist; GW4064; WAY 362450

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ACUTE PHASE PROTEIN; AMYLOID P COMPONENT; AMYLOID PROTEIN; AMYLOID PROTEIN A3; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; DRUG VEHICLE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIVER RECEPTOR HOMOLOG 1; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WAY 362450;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENTEROHEPATIC CIRCULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RISK FACTOR;

ACUTE-PHASE REACTION; ANIMALS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

MUS;

EID: 58149511929     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.117     Document Type: Article

References (30)

1. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
2. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., and Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
3. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
4. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., Koenig W., Schmitz G., Hombach V., and Torzewski J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2094-2099
5. Venugopal S.K., Devaraj S., and Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin. Nephrol. Hypertens. 14 (2005) 33-37
6. Wang C.H., Li S.H., Weisel R.D., Fedak P.W., Dumont A.S., Szmitko P., Li R.K., Mickle D.A., and Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
7. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
8. Ganapathi M.K., Rzewnicki D., Samols D., Jiang S.L., and Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J. Immunol. 147 (1991) 1261-1265
9. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
10. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
11. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., and Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101 (2003) 545-551
12. Blaschke F., Takata Y., Caglayan E., Collins A., Tontonoz P., Hsueh W.A., and Tangirala R.K. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 99 (2006) e88-e99
13. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., and Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81 (1995) 687-693
14. Rader D.J. Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol. 100 (2007) n15-n19
15. Zhang Y., and Edwards P.A. FXR signaling in metabolic disease. FEBS Lett. 582 (2008) 10-18
16. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., and Shan B. Identification of a nuclear receptor for bile acids. Science 284 (1999) 1362-1365
17. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., and Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999) 1365-1368
18. Wang H., Chen J., Hollister K., Sowers L.C., and Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3 (1999) 543-553
19. Willson T.M., Jones S.A., Moore J.T., and Kliewer S.A. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med. Res. Rev. 21 (2001) 513-522
20. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., Morelli A., Parks D.J., and Willson T.M. 6Alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45 (2002) 3569-3572
21. Li Y.T., Swales K.E., Thomas G.J., Warner T.D., and Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2606-2611
22. Li J., Wilson A., Kuruba R., Zhang Q., Gao X., He F., Zhang L.M., Pitt B.R., Xie W., and Li S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 77 (2008) 169-177
23. Evans M.J., Eckert A., Lai K., Adelman S.J., and Harnish D.C. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ. Res. 89 (2001) 823-830
24. Arnaud C., Burger F., Steffens S., Veillard N.R., Nguyen T.H., Trono D., and Mach F. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1231-1236
25. Ganter U., Arcone R., Toniatti C., Morrone G., and Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8 (1989) 3773-3779
26. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., and Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28 (2007) 940-946
27. Yang F., Huang X., Yi T., Yen Y., Moore D.D., and Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67 (2007) 863-867
28. Zhang Y., Wang X., Vales C., Lee F.Y., Lee H., Lusis A.J., and Edwards P.A. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2316-2321
29. Kim M.S., Shigenaga J., Moser A., Feingold K., and Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J. Biol. Chem. 278 (2003) 8988-8995
30. Evans M., Mahaney P.E., Zhang S., Gantan E., Borges-Marcucci L., Lai K.D., Wang S., and Harnish D.C. A synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia. Circulation 116 16, Suppl. S (2007) 106 (Abstract)